Sector News

New leader at FDA, new philosophy?

December 23, 2019
Life sciences

Stephen Hahn is the next commissioner of the FDA. What that means for the FDA and its attitude to R&D and approval standards is unclear.

Hahn came through his Senate confirmation hearing without giving away much about his views on R&D and approval standards. That is partly a reflection of questioners focusing on other topics, most notably vaping, but is also a consequence of the low-risk approach Hahn took to the hearing, where he repeatedly avoided taking hard, definitive positions by vowing to follow the science and data.

The upshot is biopharma enters a new period of the FDA without a clear read on the direction Hahn will take the agency. There were signs after Scott Gottlieb left that the agency would take a tougher line than in the past, most notably when it rejected Sarepta Therapeutics’ Vyondys 53. However, with the FDA reversing that decision months later and Hahn’s position unclear, it is questionable whether the initial Vyondys 53 rejection will be seen as a blip or a harbinger of a new approach.

Events in the new year, notably Biogen’s aducanumab filing, should start to provide some answers. However, the impact of whatever changes Hahn tries to enact may be short-lived given the potential for the Democrats to win the 2020 election and install a new leader at the FDA.

By Nick Paul Taylor

Source: Fierce Biotech

Related News

May 8, 2021

BD to spin off $1B diabetes care business into standalone public company

Life sciences

BD’s new company will have the freedom to expand its portfolio of tools and technologies for the chronic care of diabetes.

May 8, 2021

Galapagos cuts pipeline, targets €150M in savings after setbacks

Life sciences

The Belgian biotech is pulling out of metabolic diseases and osteoarthritis R&D to focus on its core therapeutic areas.

May 8, 2021

Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus

Life sciences

Catalent will use its new facility for commercial production of plasmid DNA, used to make a range of biologics, including viral vectors, mRNA and cell therapies.

Send this to a friend